甲状腺转运蛋白心脏淀粉样变分期系统中利尿剂剂量的增量价值：保持简单。 - Suppr

Suppr

超能文献

The Incremental Value of Diuretic Dose in Staging Systems for Transthyretin Cardiac Amyloid: Keep It Simple.

作者信息

Grogan Martha

机构信息

Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA.

出版信息

JACC CardioOncol. 2020 Sep 15;2(3):425-427. doi: 10.1016/j.jaccao.2020.07.004. eCollection 2020 Sep.

DOI:10.1016/j.jaccao.2020.07.004

PMID:34396249

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8352088/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6fff/8352088/30c48bd512fe/fx1.jpg

相似文献

The Incremental Value of Diuretic Dose in Staging Systems for Transthyretin Cardiac Amyloid: Keep It Simple.甲状腺转运蛋白心脏淀粉样变分期系统中利尿剂剂量的增量价值：保持简单。

JACC CardioOncol. 2020 Sep 15;2(3):425-427. doi: 10.1016/j.jaccao.2020.07.004. eCollection 2020 Sep.

Cardiac amyloidosis: updates in diagnosis and management.心脏淀粉样变性：诊断与治疗进展。

Arch Cardiovasc Dis. 2013 Oct;106(10):528-40. doi: 10.1016/j.acvd.2013.06.051. Epub 2013 Sep 23.

Transthyretin cardiac amyloidosis: an under-diagnosed cause of heart failure.转甲状腺素蛋白心脏淀粉样变性：一种诊断不足的心力衰竭病因。

J Community Hosp Intern Med Perspect. 2014 Nov 25;4(5):25500. doi: 10.3402/jchimp.v4.25500. eCollection 2014.

Beneficial Effect of Pimobendan for Severe Heart Failure Due to Transthyretin Cardiac Amyloidosis.匹莫苯丹对转甲状腺素蛋白心脏淀粉样变性所致严重心力衰竭的有益作用。

Intern Med. 2020 Feb 1;59(3):339-343. doi: 10.2169/internalmedicine.3675-19. Epub 2019 Oct 7.

Transthyretin Cardiac Amyloidosis.转甲状腺素蛋白心脏淀粉样变性

Curr Cardiol Rep. 2017 Aug 24;19(10):97. doi: 10.1007/s11886-017-0911-5.

Hereditary cardiac amyloidosis associated with Pro24Ser transthyretin mutation: a case report.与Pro24Ser转甲状腺素蛋白突变相关的遗传性心脏淀粉样变性：一例报告

J Med Case Rep. 2018 Dec 16;12(1):370. doi: 10.1186/s13256-018-1931-5.

A case of cardiac amyloidosis in an elderly Japanese patient with amyloidogenic transthyretin Val122Ile variant.一名患有淀粉样前体蛋白缬氨酸122异亮氨酸变异体的老年日本心脏淀粉样变性患者的病例。

J Cardiol Cases. 2020 Jul 29;22(5):221-225. doi: 10.1016/j.jccase.2020.07.010. eCollection 2020 Nov.

Isolated heart transplantation for familial transthyretin (TTR) V122I cardiac amyloidosis.家族性转甲状腺素蛋白（TTR）V122I 心脏淀粉样变性的心脏移植。

Amyloid. 2014 Jun;21(2):120-3. doi: 10.3109/13506129.2013.853660. Epub 2014 Feb 6.

Non-Val30Met mutation, septal hypertrophy, and cardiac denervation in patients with mutant transthyretin amyloidosis.突变转甲状腺素蛋白淀粉样变患者中的非 Val30Met 突变、室间隔肥厚和心脏去神经支配。

ESC Heart Fail. 2019 Feb;6(1):122-130. doi: 10.1002/ehf2.12361. Epub 2018 Oct 4.

Amyloid transthyretin cardiac amyloidosis: diagnosis and management.淀粉样变甲状腺素运载蛋白型心脏淀粉样变性：诊断与管理

Expert Rev Cardiovasc Ther. 2019 Sep;17(9):673-681. doi: 10.1080/14779072.2019.1662723. Epub 2019 Sep 3.

引用本文的文献

Incremental prognostic utility of congestion markers in cardiac transthyretin amyloidosis.心脏转甲状腺素蛋白淀粉样变中充血标志物的增量预后效用

Clin Res Cardiol. 2024 Aug 6. doi: 10.1007/s00392-024-02512-4.

Monitoring Tafamidis, The Most Expensive Cardiac Medication: Are Serum Transthyretin Levels the Answer?监测塔法米迪斯，最昂贵的心脏药物：血清转甲状腺素蛋白水平是答案吗？

JACC CardioOncol. 2021 Oct 19;3(4):587-589. doi: 10.1016/j.jaccao.2021.09.007. eCollection 2021 Oct.

本文引用的文献

Diuretic Dose and NYHA Functional Class Are Independent Predictors of Mortality in Patients With Transthyretin Cardiac Amyloidosis.利尿剂剂量和纽约心脏协会（NYHA）心功能分级是转甲状腺素蛋白心脏淀粉样变患者死亡率的独立预测因素。

JACC CardioOncol. 2020 Sep;2(3):414-424. doi: 10.1016/j.jaccao.2020.06.007. Epub 2020 Sep 15.

Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review.转甲状腺素蛋白淀粉样心肌病：美国心脏病学会最新临床综述

J Am Coll Cardiol. 2019 Jun 11;73(22):2872-2891. doi: 10.1016/j.jacc.2019.04.003.

Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy.特发性甲状腺素运载蛋白淀粉样变心肌病患者的塔法米迪治疗。

N Engl J Med. 2018 Sep 13;379(11):1007-1016. doi: 10.1056/NEJMoa1805689. Epub 2018 Aug 27.

A new staging system for cardiac transthyretin amyloidosis.心脏转甲状腺素蛋白淀粉样变性的新分期系统。

Eur Heart J. 2018 Aug 7;39(30):2799-2806. doi: 10.1093/eurheartj/ehx589.

AL (Light-Chain) Cardiac Amyloidosis: A Review of Diagnosis and Therapy.AL（轻链）心脏淀粉样变：诊断与治疗的综述。

J Am Coll Cardiol. 2016 Sep 20;68(12):1323-41. doi: 10.1016/j.jacc.2016.06.053.

Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System.野生型转甲状腺素蛋白心脏淀粉样变性的自然病史和使用新型分期系统进行风险分层。

J Am Coll Cardiol. 2016 Sep 6;68(10):1014-20. doi: 10.1016/j.jacc.2016.06.033.

Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis.非活检诊断心脏转甲状腺素淀粉样变性。

Circulation. 2016 Jun 14;133(24):2404-12. doi: 10.1161/CIRCULATIONAHA.116.021612. Epub 2016 Apr 22.

Potent kinetic stabilizers that prevent transthyretin-mediated cardiomyocyte proteotoxicity.强效的动力学稳定剂可防止转甲状腺素蛋白介导的心肌细胞毒性。

Sci Transl Med. 2011 Aug 24;3(97):97ra81. doi: 10.1126/scitranslmed.3002473.

Tissue damage in the amyloidoses: Transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture.淀粉样变性中的组织损伤：在组织培养中，转甲状腺素蛋白单体和非天然寡聚体是主要的细胞毒性物质。

Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):2817-22. doi: 10.1073/pnas.0400062101. Epub 2004 Feb 23.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验